Clinical trial NCT02690961: Study of Multiple-dose Kukoamine B Mesilate in Healthy Volunteers
Official title: Randomized, Double-blind Placebo-controlled Phase I Study to Assess Safety, Tolerance，Pharmacokinetics of Multiple-dose Kukoamine B Mesilate in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Healthy
Lead sponsor: Tianjin Chasesun Pharmaceutical Co., LTD
Sponsor class: INDUSTRY
Collaborators: name: Southwest Hospital, China
First posted: 2016-02-24
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess safety, tolerance and pharmacokinetics of Multiple-dose Kukoamine B Mesilate in healthy volunteers


Eligibility criteria: Inclusion Criteria:

1. Gender: male or female, each sex ratio does not exceed 2/3;
2. 18-45 years (including upper and lower limit), the general situation is good;
3. Body mass index (BMI) in 19-28 (including upper and lower limit of the range), bodyweight（BW）≥ 50kg (female) and 60kg (male);
4. Nearly half of the year, no child care program and agreed to take effective measures to contraception during the study period, women of childbearing age blood pregnancy test was negative;
5. Subjects to fully understand the purpose, properties, method and reactions may occur of test drug trials.Voluntarily signed the informed consents, and agreed to abide by the requirements of clinical protocols.

Exclusion Criteria:

1. Primary disease in important organs;
2. Mental or physical disability;
3. Familial hereditary disease;
4. Screening supine blood pressure (after 5 minutes of rest) systolic or diastolic blood pressure greater than 90-140 millimeters of mercury(mmHg), beyond the scope of 50-90 millimeters of mercury(mmHg), Or pulse (HR) beyond 50bpm-100bpm;
5. Abnormal results of any clinically meaningful physical examination, vital signs, ECG or clinical laboratory;
6. History of immunodeficiency diseases, including HIV antibody positive;
7. Detection of antibody positive, hepatitis B surface antigen or antibody to hepatitis C / syphilis positive;
8. Alcohol and drug abusers;
9. Who is addicted to alcohol and tobacco (drinking 14 units of alcohol per week: 1 unit = beer 285 ml, or liquor 25 ml, or wine 1 cup. numbers of daily smoking ≥ 5) and / or not smoking and drinking in the test period;
10. Any discharge period may affect the study drug, or in the past 3 months participated in any drug clinical trials;
11. Before entering the group 4 weeks using any prescription drugs before entering the group, or use of any non prescription drugs within 2 weeks (vitamins, herbal tonics, etc.), or into the group within 2 weeks before taking effect of drug metabolizing enzymes in food, such as grapefruit or grapefruit drink. Can the use of acetaminophen, but must record report in case report form（CRF）;
12. The last 3 months had a history of blood donation or significant blood loss (more than 400ml);
13. There are drugs, the clinical significance of the history of food allergy and atopic allergic diseases (asthma, urticaria, eczema dermatitis) or a known drug to test drugs or similar drug allergy test;
14. Lactating women, pregnant women or unable to take effective contraceptive measures;
15. Researchers believe that participants not suitable to take the test for other factors .

Primary outcomes:
measure: Incidence of adverse events.
timeFrame: 14 days
Secondary outcomes:
measure: Pharmacokinetic parameters(Maximum Plasma Concentration [Cmax])
timeFrame: the first day,the sixth day(before the three injections from bottom),the seventh day
Other outcomes:
measure: Pharmacokinetic parameters(Area Under Curve [AUC])
timeFrame: the first day,the sixth day(before the three injections from bottom),the seventh day
Locations:
city: BeiJing
country: China
facility: Peking Union Medical College Hospital
state: Beijing
Study officials:
affiliation: Tianjin Chasesun Pharmaceutical Co., LTD
name: Shuai Chen
role: STUDY_DIRECTOR
References: